COMMUNIQUÉ DE PRESSE publié le 29/06/2023 à 12:45, il y a 1 année 4 mois NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun
COMMUNIQUÉ DE PRESSE publié le 31/05/2023 à 12:40, il y a 1 année 5 mois NanoViricides, Inc. to Present at the BIO International Convention in Boston on June 5th, 2023 at 3:15pm ET
COMMUNIQUÉ DE PRESSE publié le 16/05/2023 à 12:45, il y a 1 année 6 mois NanoViricides Has Filed its Quarterly Report - Clinical Trials of Broad-Spectrum COVID Drug About to Begin
COMMUNIQUÉ DE PRESSE publié le 25/04/2023 à 12:45, il y a 1 année 6 mois NanoViricides is Expanding its Broad-Spectrum Antiviral Program to Explore Further Antiviral Applications of its COVID Clinical Drug Ingredient
COMMUNIQUÉ DE PRESSE publié le 17/04/2023 à 12:45, il y a 1 année 7 mois NanoViricides Has Shipped Drug Products for Impending Clinical Trials of NV-CoV-2, Its COVID Drug Candidate
COMMUNIQUÉ DE PRESSE publié le 04/04/2023 à 13:45, il y a 1 année 7 mois NanoViricides Signs a License Agreement That Includes Clinical Evaluation of Its COVID-19 Drug Candidates
COMMUNIQUÉ DE PRESSE publié le 15/02/2023 à 12:30, il y a 1 année 9 mois NanoViricides Has Filed its Quarterly Report - Company has Begun Production of Coronavirus Drug for Clinical Trials
COMMUNIQUÉ DE PRESSE publié le 04/01/2023 à 12:35, il y a 1 année 10 mois NanoViricides, Inc. to Present at the Biotech Showcase(TM) 2023 Conference in San Fransisco on January 9th at 10:30am PT
Publié le 21/11/2024 à 06:58, il y a 7 heures 13 minutes Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Publié le 21/11/2024 à 06:58, il y a 7 heures 13 minutes Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Publié le 21/11/2024 à 06:58, il y a 7 heures 13 minutes Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Publié le 20/11/2024 à 20:07, il y a 18 heures 3 minutes Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Publié le 20/11/2024 à 19:20, il y a 18 heures 51 minutes Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Publié le 21/11/2024 à 14:00, il y a 11 minutes Demotech, Inc. Assigns a Financial Stability Rating(R) of A, Exceptional, to Steadily Insurance Company
Publié le 21/11/2024 à 14:00, il y a 11 minutes Montara Raises $5.4M to Help Organizations Deliver Better Data Products Faster
Publié le 21/11/2024 à 14:00, il y a 11 minutes Tevir Capital LP Ltd. Updates Early Warning Reporting in Respect of VerticalScope Holdings Inc.
Publié le 21/11/2024 à 13:30, il y a 41 minutes AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue
Publié le 21/11/2024 à 13:41, il y a 30 minutes Original-Research: Pentixapharm Holding AG (von BankM AG): Kaufen
Publié le 21/11/2024 à 12:35, il y a 1 heure 35 minutes audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Publié le 21/11/2024 à 12:15, il y a 1 heure 56 minutes Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
